| scholarly article | Q13442814 |
| P50 | author | Nurlan Sandybayev | Q39064715 |
| Marina Stukova | Q54696433 | ||
| Julia Romanova | Q59680520 | ||
| Mariia Sergeeva | Q59681380 | ||
| Marianna Erofeeva | Q114817165 | ||
| Vera Z Krivitskaya | Q114817166 | ||
| P2093 | author name string | Oleg I Kiselev | |
| Abylay R Sansyzbay | |||
| Berik M Khairullin | |||
| Markhabat M Kassenov | |||
| Seidigapbar M Mamadaliyev | |||
| Zhailaubay K Kydyrbayev | |||
| P2860 | cites work | Vaccines and antiviral drugs in pandemic preparedness | Q22305646 |
| A single-dose influenza A (H5N1) vaccine safe and immunogenic in adult and elderly patients: an approach to pandemic vaccine development | Q24656615 | ||
| The neighbor-joining method: a new method for reconstructing phylogenetic trees | Q25939010 | ||
| MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) Software Version 4.0 | Q26778434 | ||
| Molecules as documents of evolutionary history | Q28256892 | ||
| Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans | Q28297557 | ||
| Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets | Q29619972 | ||
| A DNA transfection system for generation of influenza A virus from eight plasmids | Q29642855 | ||
| Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. | Q30327772 | ||
| Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. | Q30328341 | ||
| The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate. | Q30352362 | ||
| Large-scale sequence analysis of avian influenza isolates. | Q30352711 | ||
| Mitigation strategies for pandemic influenza in the United States. | Q30353646 | ||
| Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. | Q30356902 | ||
| Mass vaccination for annual and pandemic influenza. | Q30356967 | ||
| Vaccines for seasonal and pandemic influenza. | Q30358732 | ||
| A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. | Q30369945 | ||
| Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. | Q30371866 | ||
| Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and direct | Q30373391 | ||
| Safety and immunogenicity of prepandemic H5N1 influenza vaccines: a systematic review of the literature | Q30388231 | ||
| Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study | Q30403078 | ||
| Developing vaccines to combat pandemic influenza | Q30408108 | ||
| Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. | Q33974507 | ||
| Properties and dissemination of H5N1 viruses isolated during an influenza outbreak in migratory waterfowl in western China | Q34651554 | ||
| H5N1 influenza viruses: facts, not fear | Q35786879 | ||
| Rescue of influenza virus expressing GFP from the NS1 reading frame | Q45630554 | ||
| Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. | Q55041754 | ||
| Universal primer set for the full-length amplification of all influenza A viruses | Q57202943 | ||
| The efficacy of influenza vaccine for healthy children: a meta-analysis evaluating potential sources of variation in efficacy estimates including study quality | Q79679969 | ||
| P433 | issue | 8 | |
| P921 | main subject | influenza vaccine | Q383260 |
| virion | Q1757347 | ||
| P304 | page(s) | 1314-1319 | |
| P577 | publication date | 2013-06-26 | |
| P1433 | published in | Clinical and Vaccine Immunology | Q5133811 |
| P1476 | title | An inactivated, adjuvanted whole virion clade 2.2 H5N1 (A/Chicken/Astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans | |
| P478 | volume | 20 |
| Q30392533 | Clinical testing of an inactivated influenza A/H5N1 vaccine candidate in a double-blinded, placebo-controlled, randomized trial in healthy adults in Vietnam |
| Q30364635 | Considerations for the rapid deployment of vaccines against H7N9 influenza. |
| Q47587998 | Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults. |
| Q89514925 | Innate immunemodulator containing adjuvant formulated HA based vaccine protects mice from lethal infection of highly pathogenic avian influenza H5N1 virus |
| Q103024230 | Long-lasting heterologous antibody responses after sequential vaccination with A/Indonesia/5/2005 and A/Vietnam/1203/2004 pre-pandemic influenza A(H5N1) virus vaccines |
| Q30151510 | Randomized, double-blind, multi-center, phase III clinical trial to evaluate the immunogenicity and safety of MG1109 (egg-based pre-pandemic influenza A/H5N1 vaccine) in healthy adults |
| Q30372521 | Safety and immunogenicity of influenza whole inactivated virus vaccines: A phase I randomized clinical trial. |
| Q40069663 | Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: blind, randomized and placebo-controlled trial |
| Q89673485 | Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan |
| Q34686129 | The pathogenicity of swan derived H5N1 virus in birds and mammals and its gene analysis |
| Q26773027 | The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper |
Search more.